Repligen Corporation (RGEN)
NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
| 前收市價 | 159.01 |
| 開市 | 158.09 |
| 買盤 | 154.00 x 800 |
| 賣出價 | 156.00 x 1800 |
| 今日波幅 | 152.43 - 158.09 |
| 52 週波幅 | 134.64 - 225.62 |
| 成交量 | |
| 平均成交量 | 515,161 |
| 市值 | 8.64B |
| Beta 值 (5 年，每月) | 1.00 |
| 市盈率 (最近 12 個月) | 62.99 |
| 每股盈利 (最近 12 個月) | 2.46 |
| 業績公佈日 | 2023年10月30日 - 2023年11月03日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 197.62 |
BenzingaDespite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock
RBC Capital Markets has initiated coverage on Repligen Corporation (NASDAQ: RGEN) with a Sector Perform rating and a price target of $190. The analyst likes the company due to product differentiation in some of the fastest-growing areas of biopharma. But RBC is hesitant towards the stock due to the 12.7x sales multiple, lack of operational earnings beats, declining gross margins, and low absolute R&D investment relative to larger companies in the space. Related: Repligen Beefs Up Process Analyti
